Table 2.

Sensitivity, specificity, NPV, PPV, and colposcopy referral rate of three baseline triage strategies; CIN2+ and CIN3+ cases detected within 4 years were included

Endpoint CIN3+Endpoint CIN2+Total screening population
Baseline triage strategySensitivity (95% CI)Specificity (95% CI)NPV (95% CI)PPV (95% CI)Sensitivity (95% CI)Specificity (95% CI)NPV (95% CI)PPV (95% CI)Colposcopy referral rate (95% CI)Colposcopy referral rate (95% CI)
I. Cytology75.4% (67.9–81.7)78.0% (74.6–81.1)94.3 (92.0–96.0)39.7% (34.0–45.6)66.0% (59.6–71.9)81.4% (78.0–84.4)87.96% (84.5–90.2)54.5% (48.5–60.4)30.5% (27.5–33.7)1.53% (1.38–1.69)
II. Cytology/HPV1694.1% (89.1–96.9)58.8% (54.9–62.6)98.1% (96.2–99.1)30.5% (26.2–35.1)86.1% (80.9–90.0)62.6% (58.5–66.5)93.0% (90.0–95.2)43.8% (39.0–48.6)49.7% (46.5–53.0)2.49% (2.33–2.65)
III. Cytology/HPV16/1896.6% (92.3–98.5)53.6% (49.7–57.5)98.8% (97.0–99.5)28.5% (24.4–32.8)90.3% (85.7–93.5)57.6% (53.3–61.7)94.6% (91.7–96.6)41.8% (37.3–46.6)54.5% (51.2–57.6)2.73% (2.56–2.88)